期刊文献+

玻璃体腔注射抗血管内皮生长因子药物治疗年龄相关性黄斑变性引起的视网膜色素上皮撕裂的特点分析 被引量:4

Analysis of the characteristics of a retinal pigment epithelium tear after injection of intravitreal anti-vascular endothelial growth factor for the treatment of age-related macular degeneration
原文传递
导出
摘要 目的 总结分析玻璃体腔注射抗血管内皮生长因子(VEGF)药物治疗年龄相关性黄斑变性(AMD)引起的视网膜色素上皮(RPE)撕裂的临床特点.方法 文献分析.通过PubMed和中国生物医学文献光盘数据库检索系统查阅玻璃体腔注射抗VEGF药物治疗AMD引起RPE撕裂的相关文献,统计分析患者的年龄、视力、RPE撕裂的发生率及发生部位、发生RPE撕裂前玻璃体腔注药的次数及周期、玻璃体腔注射的药物种类、撕裂发生的危险因素等.结果 最终有35篇文献(7879眼)纳入研究.发生RPE撕裂的患者的平均年龄为78.6岁(59~96岁),平均玻璃体腔注药1.6次(1~次),撕裂发生后至初次诊断的平均时间间隔为34.8 d(1 d~4个月).玻璃体腔注射任何抗VEGF药物均可能会引起RPE的撕裂,RPE撕裂基本都发生在平行于色素上皮脱离(PED)的边缘.玻璃体腔注药引起RPE撕裂的发生率为0.1%~7.5%,平均1.9%.初次确诊为RPE撕裂时,与撕裂发生前相比,绝大多数患者的视力有提高或保持稳定(81.4%).经过平均94.9 d的随访,绝大多数患者的最终视力保持稳定或有提高(83.3%).大范围的血管性PED是RPE撕裂发生的危险因素,当血管性PED的高度>400μm时,玻璃体腔注药后发生RPE撕裂的危险性明显增加.结论 玻璃体腔注射抗VEGF药物治疗AMD可能会引起RPE的撕裂,但发生率较低,且RPE撕裂对大多数患者的视力无明显影响.大范围的、高的血管性PED是RPE撕裂发生的危险因素. Objective To analyze the characteristics of retinal pigment epithelium (RPE) tears following the injection of intravitreal anti-vascular endothelial growth factor (VEGF) for the treatment of age-related macular degeneration (AMD). Methods A comprehensive literature review of RPE tears following anti-VEGF therapy for AMD was conducted using the PubMed and CBM disc databases, and the features of RPE tears were summarized. Results A total of 35 studies from the literature were included. The average age of patients who developed RPE tears was 78.6 years (range 59-96 years), and the average injection times before tears developed was 1.6 (range 1-4). The mean duration time between the first injection and diagnosis was 34.8 d (range 1 d-4 months). Despite the development of RPE tears, anti-VEGF therapy can still inhibit choroidal neovascularization. Compared to visual acuity before injection, most patients had better or stable visual acuity (81.4%) even with the development of RPE tears. With an average follow-up of 94.9 days, most patients had stable or better visual acuity (83.3%). Conclusion Although anti-VEGF therapy for AMD may induce RPE tearing, this complication does not predominantly affect vision. Large-size pigment epithelial detachment (PED) is a risk factor for RPE tears, especially with large or high vascular PED.
机构地区 解放军第
出处 《中华眼视光学与视觉科学杂志》 CAS 2010年第5期378-381,共4页 Chinese Journal Of Optometry Ophthalmology And Visual Science
关键词 血管内皮生长因子 玻璃体腔注药 黄斑变性 年龄相关性 色素上皮 撕裂 Vascular endothelial growth factor Intravitreal injection Macular degeneration,age-related Retinal pigment epithelium,eye Tearing
  • 相关文献

同被引文献69

  • 1喻晓兵,戴虹,卢颖毅,龙力.光动力疗法联合玻璃体腔曲安奈德注射治疗脉络膜新生血管[J].中华眼底病杂志,2007,23(1):13-16. 被引量:20
  • 2Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES)[J]. Graefes Arch Clin Exp Ophthalmol, 2008,246( 1 ) :81-87. 被引量:1
  • 3Jonas JB, Libondi T. Study on the potential benefit of adding topical brorrffenac to intravitreal injections of ranibizumab for the therapy of exudative age-related macutar degeneration [J]. Retina,2013,33 (5) : 1093. 被引量:1
  • 4Gomi F, Sawa M, Tsujikawa M, et al. Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration[J]. Retina,2012,32 (9):1804-1810. 被引量:1
  • 5Flaxel C, Schain MB, Hamon SC, et al. Prospective randomized controlled trial of combination ranibizmnab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration : a pilot study[J]. Retina, 2012,32 (3) : 417-423. 被引量:1
  • 6Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections[J]. Ophthalmic Surg Lasers Imaging,2009,40(3:293- 295. 被引量:1
  • 7Querques G. Anti-Vascular Endothelial Growth Factor Injection for Exudative Age-related Maeular Degeneration in Patients with Vitreo-Macular Traction[J]. Am J Ophthalmol,2009,147(2): 375-376,376-377. 被引量:1
  • 8van Wijngaarden P, Qureshi SH. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age- related macular degeneration: a review of current practice[J]. Clin Exp Optom,2008,91 (5) :427-437. 被引量:1
  • 9Hohman TC. Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases[J]. Retina, 2009,29 ( 6 Suppl) : S51 -S53. 被引量:1
  • 10Afzal A, Shaw LC, Ljubimov AV, et al. Retinal and choroidal microangiopathies: therapeutic opportunities[J]. Microvasc Res, 2007,74(2-3) : 131-144. 被引量:1

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部